000127299 001__ 127299
000127299 005__ 20240228140917.0
000127299 0247_ $$2doi$$a10.1016/j.ygeno.2015.10.002
000127299 0247_ $$2pmid$$apmid:26453961
000127299 0247_ $$2ISSN$$a0888-7543
000127299 0247_ $$2ISSN$$a1089-8646
000127299 0247_ $$2altmetric$$aaltmetric:4610594
000127299 037__ $$aDKFZ-2017-03324
000127299 041__ $$aeng
000127299 082__ $$a610
000127299 1001_ $$0P:(DE-He78)83906db1355a576371363a4b9f107d3d$$aPfütze, Katrin$$b0$$eFirst author$$udkfz
000127299 245__ $$aMethylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.
000127299 260__ $$aSan Diego, Calif.$$bAcademic Press$$c2015
000127299 3367_ $$2DRIVER$$aarticle
000127299 3367_ $$2DataCite$$aOutput Types/Journal article
000127299 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521707934_2108
000127299 3367_ $$2BibTeX$$aARTICLE
000127299 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127299 3367_ $$00$$2EndNote$$aJournal Article
000127299 520__ $$aDNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.
000127299 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000127299 588__ $$aDataset connected to CrossRef, PubMed,
000127299 650_7 $$2NLM Chemicals$$aAntimetabolites, Antineoplastic
000127299 650_7 $$2NLM Chemicals$$aCell Adhesion Molecules
000127299 650_7 $$2NLM Chemicals$$aGPI-Linked Proteins
000127299 650_7 $$0EC 3.2.1.25$$2NLM Chemicals$$aHyal2 protein, human
000127299 650_7 $$0EC 3.2.1.35$$2NLM Chemicals$$aHyaluronoglucosaminidase
000127299 650_7 $$0U3P01618RT$$2NLM Chemicals$$aFluorouracil
000127299 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b1$$udkfz
000127299 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000127299 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b3$$udkfz
000127299 7001_ $$0P:(DE-He78)dd35af1fb84ec0812fe4bdea97d2f291$$aYang, Rongxi$$b4$$udkfz
000127299 7001_ $$aBläker, Hendrik$$b5
000127299 7001_ $$0P:(DE-HGF)0$$aHerpel, Esther$$b6
000127299 7001_ $$aUlrich, Alexis$$b7
000127299 7001_ $$0P:(DE-HGF)0$$aUlrich, Cornelia M$$b8
000127299 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b9$$udkfz
000127299 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000127299 7001_ $$0P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aBurwinkel, Barbara$$b11$$eLast author$$udkfz
000127299 773__ $$0PERI:(DE-600)1468023-3$$a10.1016/j.ygeno.2015.10.002$$gVol. 106, no. 6, p. 348 - 354$$n6$$p348 - 354$$tGenomics$$v106$$x0888-7543$$y2015
000127299 909CO $$ooai:inrepo02.dkfz.de:127299$$pVDB
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)83906db1355a576371363a4b9f107d3d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)dd35af1fb84ec0812fe4bdea97d2f291$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000127299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000127299 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000127299 9141_ $$y2015
000127299 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127299 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGENOMICS : 2015
000127299 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127299 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127299 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127299 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127299 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127299 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127299 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127299 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127299 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127299 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127299 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000127299 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127299 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000127299 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x0
000127299 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000127299 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x2
000127299 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x3
000127299 9201_ $$0I:(DE-He78)G035-20160331$$kG035$$lTumor- und Serumbank$$x4
000127299 9201_ $$0I:(DE-He78)C080-20160331$$kC080$$lMolekulare Epidemiologie$$x5
000127299 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x6
000127299 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x7
000127299 980__ $$ajournal
000127299 980__ $$aVDB
000127299 980__ $$aI:(DE-He78)G100-20160331
000127299 980__ $$aI:(DE-He78)C060-20160331
000127299 980__ $$aI:(DE-He78)C070-20160331
000127299 980__ $$aI:(DE-He78)G010-20160331
000127299 980__ $$aI:(DE-He78)G035-20160331
000127299 980__ $$aI:(DE-He78)C080-20160331
000127299 980__ $$aI:(DE-He78)G110-20160331
000127299 980__ $$aI:(DE-He78)L101-20160331
000127299 980__ $$aUNRESTRICTED